Pearl Steinzor

Despite the use of nocturnal noninvasive ventilation (NIV), patients report having poor quality of sleep, according to a recent study.

Children with severe asthma who moved to better-resourced neighborhoods in Baltimore showed improvement of symptoms, according to a recent study.

Melinda Gooderham, MD, MSc, FRCPC, Peterborough Regional Health Centre in Ontario, Canada, discusses recent trials and studies that have been conducted on emerging therapies for patients with atopic dermatitis.

Chronic obstructive pulmonary disease (COPD) exacerbations and oral corticosteroid use dropped in patients treated with monoclonal antibodies targeting interleukin (IL)-5 and its receptor (IL-5R), a study found.

Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health, discusses the role the new wave of biosimilars will have on rebate practices for both pharmacy benefit managers (PBMs) and payers.

A recent survey assessed the factors that adult patients with eczema and caregivers find important regarding clinical trial participation decision-making.

Neal Dave, PharmD, executive director of pharmacy operations at Texas Oncology, discusses updates to the National Community Oncology Dispensing Association (NCODA) Center of Excellence pharmacy accreditation program.

Individuals with chronic obstructive pulmonary disease (COPD) experience improved breathing symptoms and dyspnea with use of automated oxygen administration.

Connie Sullivan, president and CEO of the National Home Infusion Association (NHIA), discusses why at-home infusion is beneficial to patients and why so many patients reported feeling satisfied with home administration.

Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health, discusses what's to come as a result of a "second wave" of biosimilars hitting the market.

Current cigarette and electronic nicotine delivery systems (ENDS) were associated with elevated wheezing, but not ENDS use alone, according to a new study.

Andy Blauvelt, MD, MBA, president of Oregon Medical Research Center, discusses the use of systemic therapies vs biologics and why adherence is so important when treating patients with atopic dermatitis (AD).

Larry Eichenfield, MD, professor of dermatology and pediatrics and vice chair of the Department of Dermatology at the University of California San Diego School of Medicine and chief of pediatric and adolescent dermatology at Rady Children's Hospital San Diego, discusses the use of different treatments and biologics for atopic dermatitis (AD) in infants, which he presented at the Revolutionizing Atopic Dermatitis conference.

A positive association between asthma and overall cancer risk was found, according to this new study.

Melinda Gooderham, MSc, MD, FRCPC, dermatologist and clinical researcher at Peterborough Regional Health Centre, discusses emerging topical and biologic therapies expected to be available later this year.

Robert Sidbury, MD, MPH, professor of pediatrics at Seattle Children's Hospital, discusses treatment approaches for atopic dermatitis of the face in infancy, which he presented at the Revolutionizing Atopic Dermatitis conference.

On this episode of Managed Care Cast, we speak with Bruce W. Sherman, MD, of Case Western Reserve University School of Medicine, about a recent study on wage-level disparities affecting the utilization of mental health resources, for which he was lead investigator; the study article appears in the April issue of The American Journal of Managed Care®.

The study examined the prevalence of prescription medications in jails and state prisons for individuals with chronic conditions, such as asthma, type 2 diabetes, hypertension, hepatitis B and C, HIV infection, depression, and severe mental illness, compared with the general population.

Jonathan Silverberg, MD, PhD, MPH, professor of dermatology and director of clinical research and patch testing at the George Washington University School of Medicine and Health Sciences, and chair of the Revolutionizing Atopic Dermatitis (RAD) conference, discusses some of the symposia and events at this year's conference that he is looking forward to the most.

Improved survival rates suggest long-term noninvasive therapy (LTH-NIV) may benefit patients with acute hypercapnic exacerbations of chronic obstructive pulmonary disorder (AECOPD).

For patients with aspirin-exacerbated respiratory disease (AERD), omalizumab significantly reduced their symptoms, according to one study.

Individuals with severe type 2 asthma and chronic rhinosinusitis with nasal polyps may benefit from the biologic treatment, dupilumab.

Judy Alberto, MHA, RPh, BCOP, director of clinical initiatives at the Community Oncology Alliance, discusses the importance of making sure oncology practices are educated about their value-based enterprise exception when mailing patients their cancer medications.

Debra Patt, MD, PhD, MBA, executive vice president at Texas Oncology, explains the small potential risk of breast cancer associated with hormonal birth control.

Shiela Plasencia, director of practice support at the Community Oncology Alliance, discusses the benefits of collecting social determinants of health data for both the patient and provider.

Sleep and genetics play individual roles in increasing a person’s risk for asthma, but their combination also heightens that risk.

Physicians may be able to better identify patients with chronic cough using the combination of 2 coughing tests.

Amy Valley, vice president for clinical strategy and technology solutions at Cardinal Health, weighs both the benefits and potential risks of physicians using artificial intelligence technology in their oncology practices.

Kathy Oubre, MS, CEO of Pontchartrain Cancer Center, discusses the use of biosimilars and how pharmacy benefit managers (PBMs) as well as payers have challenged the biosimilar market.

People with chronic obstructive pulmonary disease (COPD) are at increased risk of long-term hearing loss, researchers find.